Intas Pharmaceuticals Partners with IntegriMedical to Launch India's First Needle-Free IVF Injection System
Key Insights
Intas Pharmaceuticals has entered an exclusive collaboration with IntegriMedical (search) to introduce India's first needle-free injection system specifically for IVF (search) and gynecology (search) treatments.
The innovative technology uses a high-pressure jet stream mechanism to deliver medications through micro-orifices without needles, reducing patient discomfort and anxiety.
With India conducting 300,000-350,000 IVF (search) cycles annually and projections reaching 500,000-600,000 by 2027, this advancement could impact millions of injections administered yearly.
Intas Pharmaceuticals has announced a groundbreaking exclusive partnership with IntegriMedical (search) to introduce India's first needle-free injection system for IVF (search) and gynecology (search) treatments, marking a significant advancement in reproductive healthcare delivery. This collaboration positions Intas as the pioneering company in the country to offer such advanced therapeutic techniques, fundamentally transforming the patient experience in fertility treatments (search).
Revolutionary Technology Addresses Critical Patient Needs
The Needle-Free Injection System (N-FIS) employs a sophisticated high-pressure jet stream mechanism that delivers medication through a micro-orifice in the skin without traditional needles. This spray-like delivery pattern ensures precise medication administration while significantly reducing tissue impact, avoiding medication pooling, and lowering the risk of cross-contamination.
"This initiative is about more than introducing a new technology; it's about changing how patients experience care," said Durga P Satapathy, Executive Vice President at Intas. "IVF (search) and gynecology (search) treatments can be demanding, and our goal is to make every step easier, more reassuring, and more dignified."
Addressing India's Growing IVF Market
The timing of this innovation is particularly significant given India's expanding fertility treatment landscape. The country currently records an estimated 300,000 to 350,000 IVF (search) cycles annually, with projections indicating potential growth to 500,000 to 600,000 cycles by 2027. This translates to several million injections administered each year as part of IVF treatment protocols across India.
The integration of needle-free injection technology is expected to substantially impact the treatment experience for women undergoing these procedures, addressing the significant burden of injection-related discomfort and anxiety that often accompanies fertility treatments (search).
Patient-Centric Innovation Focus
Sarvesh Mutha, Managing Director of IntegriMedical (search), emphasized the human-centered approach driving this collaboration: "It's incredibly rewarding to see our vision come to life through this groundbreaking collaboration with Intas. For IntegriMedical, this is more than a technical achievement, it's about making treatments less intimidating, more comfortable, and truly humane."
The partnership specifically targets injection-related challenges that can compromise treatment compliance and patient satisfaction. By eliminating needles, the system aims to minimize pain, anxiety, and treatment fatigue that hundreds of thousands of women experience annually during their reproductive care (search) journey.
Implementation and Market Impact
Under the exclusive agreement, Intas and IntegriMedical (search) will collaborate to deploy the needle-free injection system across IVF (search) clinics and gynecology (search) centers throughout India. This nationwide rollout represents a fundamental shift in how reproductive medications are administered, potentially setting new standards for patient-centric drug delivery systems in the country.
The collaboration leverages IntegriMedical (search)'s specialized drug delivery technology, which has been specifically developed as India's needle-free injection system. This domestic innovation addresses the unique needs of the Indian healthcare market while establishing new benchmarks for care quality and patient comfort in reproductive medicine.